Ketamine is under clinical development by PharmaTher and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ketamine overview

Ketamine is under development for the treatment of status epilepticus, rett syndrome, amyotrophic lateral sclerosis (Lou Gehrig's disease), complex regional pain syndrome, depression, post-traumatic stress disorder, levodopa-induced dyskinesia in Parkinson's disease and ischemia-reperfusion injury from organ transplantation. It is administered through intravenous route. It is a psychedelic drug, which acts by targeting N-methyl-D-aspartate (NMDA) receptor. The drug candidate is being developed based on gelatin methacryloyl microneedle (GelMA-MN) delivery technology.

PharmaTher overview

PharmaTher (PharmaThers) is a clinical-stage biotech company focused on the research, development, and commercialization of novel uses formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. It is headquartered in Toronto, Ontario, Canada.

For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.